A dual GIP/GLP-1 receptor co-agonist that simultaneously activates both incretin pathways. By targeting GIP and GLP-1 receptors, it enhances insulin secretion, suppresses glucagon, slows gastric emptying, and powerfully reduces appetite through central nervous system signaling. This dual action delivers superior glycemic control and more pronounced weight loss compared to single GLP-1 agonists.
